3+ mon, 1+ week ago   (193+ words) MESA, AZ / ACCESS Newswire / June 1, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE), ("MDCE" or the "Company") a technology company focused on AI-powered imaging and wellness applications, today provided additional details regarding the user experience and interface design objectives currently being…...

3+ mon, 1+ week ago   (308+ words) New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across…...

3+ mon, 1+ week ago   (530+ words) Grants totalling in excess of £2.2M awarded from two industry leading innovation fundsThe new grants will support the development of Laverock’s single-cell and AI powered gene-control platform, alongside pipeline expansion into additional therapeutic areas.LONDON--(BUSINESS WIRE)--Laverock Therapeutics (‘Laverock’), a…...

3+ mon, 2+ week ago   (155+ words) Dr. Ran Rubinstein introduces BioRePeel to both New York and New Jersey practices as demand grows for no-downtime skin rejuvenation treatments. A New Option for Patients Who Want Results Without the Downtime What Sets BioRePeel Apart A Peel That Fits…...

3+ mon, 2+ week ago   (144+ words) BLEEDnFIRE pioneers first RNA therapy targeting protein S, key regulator of coagulation cascade, offering new therapeutic strategy for patients across multiple rare bleeding disorders Support from Innosuisse and Venture Kick positions BLEEDnFIRE for next stage development and financing round In…...

3+ mon, 2+ week ago   (796+ words) NeoCircle study, published in the journal EMBO Molecular Medicine, shows that Pathlight™ detects relapse up to four years ahead of clinical progression and outperforms pathologic complete response as a prognostic markerMORRISVILLE, N.C.--(BUSINESS WIRE)--#BreastCancer--SAGA Diagnostics, a pioneer in tumor-informed…...

3+ mon, 3+ week ago   (206+ words) Phase 1 of the program involves the solid-phase synthesis, purification, and analytical characterization of a highly active macromolecule delivery agent of relevance to LIR's transdermal delivery platform. Neuland will produce approximately 200 mg of an efficient transdermal agent as part of this…...

3+ mon, 3+ week ago   (580+ words) UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with…...

3+ mon, 3+ week ago   (739+ words) Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance therapySAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--#CancerGenome--Inocras, a bioinformatics-led company harnessing the power of whole-genome data…...

3+ mon, 3+ week ago   (130+ words) MORRISVILLE, N.C.--(BUSINESS WIRE)--#ASCO2026--SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual…...